Sumitomo Life Insurance Co. acquired a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 9,759 shares of the company’s stock, valued at approximately $1,200,000.
A number of other institutional investors have also recently made changes to their positions in the business. Principal Financial Group Inc. boosted its stake in shares of Neurocrine Biosciences by 1.6% in the 1st quarter. Principal Financial Group Inc. now owns 78,956 shares of the company’s stock valued at $6,547,000 after purchasing an additional 1,234 shares in the last quarter. Fox Run Management L.L.C. acquired a new stake in Neurocrine Biosciences during the 3rd quarter worth approximately $234,000. Cubist Systematic Strategies LLC bought a new position in Neurocrine Biosciences during the 2nd quarter worth approximately $216,000. Swiss National Bank raised its holdings in Neurocrine Biosciences by 1.8% during the 2nd quarter. Swiss National Bank now owns 156,500 shares of the company’s stock worth $15,375,000 after purchasing an additional 2,800 shares during the last quarter. Finally, NumerixS Investment Technologies Inc raised its holdings in Neurocrine Biosciences by 90.9% during the 2nd quarter. NumerixS Investment Technologies Inc now owns 2,100 shares of the company’s stock worth $204,000 after purchasing an additional 1,000 shares during the last quarter.
Several research analysts have issued reports on the stock. Cantor Fitzgerald set a $150.00 price target on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a report on Monday, November 5th. Morgan Stanley lowered their price objective on shares of Neurocrine Biosciences from $145.00 to $135.00 and set a “buy” rating for the company in a research note on Tuesday. Needham & Company LLC set a $125.00 price objective on shares of Neurocrine Biosciences and gave the company a “buy” rating in a research note on Wednesday, August 1st. Stifel Nicolaus initiated coverage on shares of Neurocrine Biosciences in a research note on Tuesday, August 7th. They issued a “buy” rating and a $137.00 price objective for the company. Finally, Piper Jaffray Companies set a $111.00 price objective on shares of Neurocrine Biosciences and gave the company a “buy” rating in a research note on Tuesday. One investment analyst has rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $124.88.
NBIX traded down $2.90 during mid-day trading on Friday, reaching $105.41. 744,889 shares of the stock were exchanged, compared to its average volume of 776,003. The company has a market capitalization of $9.84 billion, a price-to-earnings ratio of -65.07, a P/E/G ratio of 34.87 and a beta of 0.94. Neurocrine Biosciences, Inc. has a 1 year low of $67.32 and a 1 year high of $126.98.
Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings data on Monday, November 5th. The company reported $0.52 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.48 by $0.04. The firm had revenue of $151.80 million for the quarter, compared to the consensus estimate of $151.51 million. Neurocrine Biosciences had a net margin of 2.40% and a return on equity of 2.54%. The business’s revenue for the quarter was up 149.7% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.13) EPS. As a group, sell-side analysts forecast that Neurocrine Biosciences, Inc. will post 0.17 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This report was reported by BBNS and is owned by of BBNS. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://baseballnewssource.com/2018/11/10/sumitomo-life-insurance-co-takes-position-in-neurocrine-biosciences-inc-nbix/2847380.html.
Neurocrine Biosciences Profile
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease.
See Also: What does earnings per share mean?
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.